Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.

Anna Vanazzi, MD, Pier Francesco Ferrucci, MD, Chiara Grana, MD, Marta Cremonesi, MPh, Margherita Clerici, RN, Davide Radice, ST, Stefano Papi, PhD, Liliana Calabrese, DM, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2007) 110 (11): 1890.

https://doi.org/10.1182/blood.V110.11.1890.1890

Published: 2007

Journal Articles

Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).

Anna Vanazzi, MD, Pier Francesco Ferrucci, MD, Chiara Grana, MD, Giancarlo Pruneri, MD, Cristiano Crosta, MD, Antonello Pinto, MD, Marco Chinol, PhD, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2007) 110 (11): 4499.

https://doi.org/10.1182/blood.V110.11.4499.4499

Published: 2007

Journal Articles

High Dose 90 Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.

Anna Vanazzi, MD, Pier Francesco Ferrucci, MD, Chiara Grana, MD, Marta Cremonesi, MPH, Margherita Clerici, RN, Davide Radice, ST, STefano Papi, Liliana Calabrese, DM, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2006) 108 (11): 2720.

https://doi.org/10.1182/blood.V108.11.2720.2720

Published: 2006

Journal Articles

Efficacy of 90 Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkin’s Lymphoma.

Anna Vanazzi, MD, Pier F. Ferrucci, MD, Chiara Grana, MD, Giancarlo Pruneri, MD, Cristiano Crosta, MD, Antonello Pinto, MD, Marco Chinol, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2006) 108 (11): 2771.

https://doi.org/10.1182/blood.V108.11.2771.2771

Published: 2006

Journal Articles

High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study.

Anna Vanazzi, MD, Pierfrancesco Ferrucci, MD, Mahila Ferrari, Liliana Calabrese, Marta Cremonesi, Mirco Bartolomei, MD, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2005) 106 (11): 488.

https://doi.org/10.1182/blood.V106.11.488.488

Published: 2005

NARROW

High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.

Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).

High Dose 90 Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.

Efficacy of 90 Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkin’s Lymphoma.

High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study.

Email alerts

ASH Publications

American Society of Hematology

High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.

Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).

High Dose 90 Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.

Efficacy of 90 Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkin’s Lymphoma.

High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only